Barinthus Biotherapeutics Plc ADR (BRNS)

$1.42 +0.40 (39.22%)
Market Cap 41.15M
Revenue (ttm) 14.97M
Net Income (ttm) -61.07M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -407.95%
Debt to Equity Ratio 0.00
Volume 69,825,906
Avg Vol 1,427,428
Day's Range N/A - N/A
Shares Out 40.34M
Stochastic %K 25%
Beta -0.80
Analysts Strong Sell
Price Target $5.33

Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targeting chronic hepatitis B virus infection; VTP-200, a potential non-invasive treatment for persistent hig...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 1865 818 808
Address:
Zeus Building, Unit 6-10 Rutherford Avenue Harwell, Didcot, United Kingdom
ClenchFists
ClenchFists Jul. 17 at 10:24 AM
$BRNS it's no over!!
0 · Reply
BUKUDATBULL
BUKUDATBULL Jul. 17 at 10:12 AM
$BRNS 🤔hmmmmm now🫨🫢😶........??????
0 · Reply
whatabull
whatabull Jul. 17 at 8:50 AM
$BRNS please, drop a mega big good news!
0 · Reply
Mtxyz
Mtxyz Jul. 17 at 2:28 AM
$BRNS You bulls will make money tomorrow……… No technical analysis, solely on the bases that I didn’t enter when I should have.
0 · Reply
StockScanners
StockScanners Jul. 17 at 1:22 AM
$BRNS Keep watch if this gets back above 1.50
0 · Reply
PIONEER888
PIONEER888 Jul. 17 at 12:23 AM
$BRNS back to 2$ tomorrow
0 · Reply
Dreamer89
Dreamer89 Jul. 16 at 9:14 PM
$BRNS jeahhhh what a donkey stock.. Loll warned you 😂😂😂😂😂
0 · Reply
IntraTrades
IntraTrades Jul. 16 at 8:39 PM
$YHC 132.75% $SDM 46.68% $APM 45.86% $BRNS 39.23% $HUBC 35.67%
1 · Reply
funnymoney90210
funnymoney90210 Jul. 16 at 8:24 PM
$BRNS wow!
0 · Reply
MaksD
MaksD Jul. 16 at 8:14 PM
Red day for me. On both $APM $BRNS didn’t fixed small gain, was expecting to hit my PTs or lose a bit. Stop loss triggered $APM $BRNS
1 · Reply
Latest News on BRNS
Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025

Jun 9, 2025, 9:00 AM EDT - 5 weeks ago

Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025

Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments

Mar 20, 2025, 7:22 AM EDT - 4 months ago

Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments

Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11

Mar 6, 2025, 8:30 AM EST - 4 months ago

Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11

Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update

Jan 10, 2025, 8:00 AM EST - 6 months ago

Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update

Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer

Nov 25, 2024, 4:01 PM EST - 8 months ago

Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer

Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion

Nov 15, 2024, 11:02 AM EST - 8 months ago

Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

Nov 15, 2024, 11:01 AM EST - 8 months ago

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results

Nov 6, 2024, 8:00 AM EST - 9 months ago

Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results

Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections

Jun 12, 2024, 4:01 PM EDT - 1 year ago

Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections

Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B

Jun 6, 2024, 11:15 AM EDT - 1 year ago

Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B

Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments

May 13, 2024, 8:00 AM EDT - 1 year ago

Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments

Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer

May 1, 2024, 7:00 AM EDT - 1 year ago

Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer

Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections

Apr 18, 2024, 4:10 PM EDT - 1 year ago

Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections

Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments

Mar 20, 2024, 8:15 AM EDT - 1 year ago

Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments

Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones

Jan 5, 2024, 4:01 PM EST - 1 year ago

Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones

New partnership aims to advance vaccine against MERS coronavirus

Dec 21, 2023, 7:31 AM EST - 1 year ago

New partnership aims to advance vaccine against MERS coronavirus

Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD

Nov 9, 2023, 4:24 PM EST - 1 year ago

Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD

Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments

Nov 9, 2023, 4:01 PM EST - 1 year ago

Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments

Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer

Nov 6, 2023, 9:05 AM EST - 1 year ago

Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer

Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023

Sep 13, 2023, 8:00 AM EDT - 2 years ago

Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023

Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

Aug 10, 2023, 8:00 AM EDT - 2 years ago

Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B

Jun 21, 2023, 9:03 AM EDT - 2 years ago

Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B

Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy

Jun 12, 2023, 7:30 AM EDT - 2 years ago

Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy

Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments

May 12, 2023, 8:00 AM EDT - 2 years ago

Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments

Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B

Mar 28, 2023, 8:00 AM EDT - 2 years ago

Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B

Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments

Mar 24, 2023, 8:06 AM EDT - 2 years ago

Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments

Vaccitech to Host KOL Webinar on the SNAPvax™ Platform for Inducing Tolerance to Treat Celiac and other Autoimmune Diseases

Nov 21, 2022, 10:31 AM EST - 2 years ago

Vaccitech to Host KOL Webinar on the SNAPvax™ Platform for Inducing Tolerance to Treat Celiac and other Autoimmune Diseases

Vaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

Nov 10, 2022, 4:30 PM EST - 2 years ago

Vaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

Vaccitech Provides Update on Ongoing VTP-300 Phase 1b/2a Trial Showing Sustained Reductions of HBsAg in Patients with Chronic Hepatitis B

Nov 7, 2022, 8:00 AM EST - 2 years ago

Vaccitech Provides Update on Ongoing VTP-300 Phase 1b/2a Trial Showing Sustained Reductions of HBsAg in Patients with Chronic Hepatitis B

Vaccitech Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® Providing Update on the Phase 1b/2a Study of VTP-300

Nov 2, 2022, 8:00 AM EDT - 2 years ago

Vaccitech Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® Providing Update on the Phase 1b/2a Study of VTP-300

Vaccitech to Present at Upcoming October Investor & Scientific Conferences

Oct 3, 2022, 4:30 PM EDT - 3 years ago

Vaccitech to Present at Upcoming October Investor & Scientific Conferences

Vaccitech Promotes Gemma Brown as Chief Financial Officer

Sep 20, 2022, 4:30 PM EDT - 3 years ago

Vaccitech Promotes Gemma Brown as Chief Financial Officer

Vaccitech to Present at Upcoming September Investors Conferences

Sep 7, 2022, 4:01 PM EDT - 3 years ago

Vaccitech to Present at Upcoming September Investors Conferences

Vaccitech Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

Aug 9, 2022, 4:15 PM EDT - 3 years ago

Vaccitech Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

Vaccitech to Present at the William Blair Biotech Focus Conference 2022

Jul 7, 2022, 4:15 PM EDT - 3 years ago

Vaccitech to Present at the William Blair Biotech Focus Conference 2022

Vaccitech's Vaccine Induced Sustained Reductions In Hepatitis B Associated Antigens

Jun 22, 2022, 1:48 PM EDT - 3 years ago

Vaccitech's Vaccine Induced Sustained Reductions In Hepatitis B Associated Antigens

Vaccitech's VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1

Jun 22, 2022, 6:00 AM EDT - 3 years ago

Vaccitech's VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1

Vaccitech to Present at the Jefferies Healthcare Conference

Jun 6, 2022, 4:15 PM EDT - 3 years ago

Vaccitech to Present at the Jefferies Healthcare Conference

Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus

Jun 6, 2022, 7:32 AM EDT - 3 years ago

Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus

Vaccitech to Present at the H.C. Wainwright Global Investment Conference

May 20, 2022, 11:30 AM EDT - 3 years ago

Vaccitech to Present at the H.C. Wainwright Global Investment Conference

Vaccitech Reports First Quarter 2022 Financial Results and Recent Corporate Developments

May 11, 2022, 4:15 PM EDT - 3 years ago

Vaccitech Reports First Quarter 2022 Financial Results and Recent Corporate Developments

Vaccitech Announces Notification of Milestone and Royalty Revenue Relating to Sales of Vaxzevria®

Apr 6, 2022, 4:15 PM EDT - 3 years ago

Vaccitech Announces Notification of Milestone and Royalty Revenue Relating to Sales of Vaxzevria®

Vaccitech: Aiming For A Cure In Chronic Hepatitis B

Apr 3, 2022, 7:57 PM EDT - 3 years ago

Vaccitech: Aiming For A Cure In Chronic Hepatitis B

Vaccitech Reports Full-Year 2021 Financial Results and Recent Corporate Developments

Mar 25, 2022, 7:15 AM EDT - 3 years ago

Vaccitech Reports Full-Year 2021 Financial Results and Recent Corporate Developments

Vaccitech to Present at the Barclays Global Healthcare Conference 2022

Mar 7, 2022, 8:00 AM EST - 3 years ago

Vaccitech to Present at the Barclays Global Healthcare Conference 2022

Cancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer Immunotherapy Vaccine

Jan 18, 2022, 3:00 AM EST - 3 years ago

Cancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer Immunotherapy Vaccine

Vaccitech to Host Virtual KOL Event on VTP-300, a Potential Functional Cure for Chronic Hepatitis B (CHB) Infection, and the Broader CHB Therapeutics Landscape

Jan 13, 2022, 4:34 PM EST - 3 years ago

Vaccitech to Host Virtual KOL Event on VTP-300, a Potential Functional Cure for Chronic Hepatitis B (CHB) Infection, and the Broader CHB Therapeutics Landscape

Vaccitech acquires Avidea Technologies to expand product pipeline and strengthen scientific leadership in immunotherapies and vaccines

Dec 13, 2021, 4:05 PM EST - 3 years ago

Vaccitech acquires Avidea Technologies to expand product pipeline and strengthen scientific leadership in immunotherapies and vaccines

Vaccitech Posts Interim Efficacy Data From Early-Stage Hepatitis B Trial

Dec 7, 2021, 9:49 AM EST - 3 years ago

Vaccitech Posts Interim Efficacy Data From Early-Stage Hepatitis B Trial

Vaccitech to Participate at The 33rd Annual Virtual Piper Sandler Healthcare Conference

Nov 24, 2021, 9:20 AM EST - 3 years ago

Vaccitech to Participate at The 33rd Annual Virtual Piper Sandler Healthcare Conference

ClenchFists
ClenchFists Jul. 17 at 10:24 AM
$BRNS it's no over!!
0 · Reply
BUKUDATBULL
BUKUDATBULL Jul. 17 at 10:12 AM
$BRNS 🤔hmmmmm now🫨🫢😶........??????
0 · Reply
whatabull
whatabull Jul. 17 at 8:50 AM
$BRNS please, drop a mega big good news!
0 · Reply
Mtxyz
Mtxyz Jul. 17 at 2:28 AM
$BRNS You bulls will make money tomorrow……… No technical analysis, solely on the bases that I didn’t enter when I should have.
0 · Reply
StockScanners
StockScanners Jul. 17 at 1:22 AM
$BRNS Keep watch if this gets back above 1.50
0 · Reply
PIONEER888
PIONEER888 Jul. 17 at 12:23 AM
$BRNS back to 2$ tomorrow
0 · Reply
Dreamer89
Dreamer89 Jul. 16 at 9:14 PM
$BRNS jeahhhh what a donkey stock.. Loll warned you 😂😂😂😂😂
0 · Reply
IntraTrades
IntraTrades Jul. 16 at 8:39 PM
$YHC 132.75% $SDM 46.68% $APM 45.86% $BRNS 39.23% $HUBC 35.67%
1 · Reply
funnymoney90210
funnymoney90210 Jul. 16 at 8:24 PM
$BRNS wow!
0 · Reply
MaksD
MaksD Jul. 16 at 8:14 PM
Red day for me. On both $APM $BRNS didn’t fixed small gain, was expecting to hit my PTs or lose a bit. Stop loss triggered $APM $BRNS
1 · Reply
topstockalerts
topstockalerts Jul. 16 at 8:12 PM
Todays Top Gainers PT2 $SRM $GTI $OPEN $BRNS $DPRO
1 · Reply
DavidScott
DavidScott Jul. 16 at 8:02 PM
$BRNS = Woohoo! Awesome work bulls. The bears got wrecked earlier today! Let's go ahead and teach these shorts another valuable lesson again tomorrow 💎🏦👊
0 · Reply
MamaR
MamaR Jul. 16 at 7:59 PM
$BRNS saving some powder for AHs. Looking for a move back towards VWAP
0 · Reply
DavidScott
DavidScott Jul. 16 at 7:51 PM
$GTI $BRNS $PHUN $CAN $FFAI = Nice job everyone! The bulls had some solid movers today. These were our main trades, and we are bullish and expecting even more momentum on these names again going into Thursday. If you need any guidance or a mentor, then feel free to join our team anytime! ✅🙌 Have a great day everybody! 🎉
0 · Reply
clockwork331
clockwork331 Jul. 16 at 7:47 PM
$BRNS Covered all 2000 at $1.36. Probably should've held into after hours but I don't know if this will do a bounce back to VWAP AH.
0 · Reply
Slitherin
Slitherin Jul. 16 at 7:46 PM
$ZKIN mark my words. This hit $5+ very soon. Crypto is going sky high 😝 News inbound this week or next 👀 Watching : $BRNS $SBET $SRM $YHC
0 · Reply
WilliamGreene83
WilliamGreene83 Jul. 16 at 7:45 PM
$BRNS
0 · Reply
ucantcatchmegaythots
ucantcatchmegaythots Jul. 16 at 7:41 PM
$BRNS it will push our pins of the close
0 · Reply
Alessandro437
Alessandro437 Jul. 16 at 7:38 PM
$BRNS bought the dip 🚀 Easy hold 0 shorts available 🚀☢️
0 · Reply
topstockalerts
topstockalerts Jul. 16 at 7:27 PM
Top Movers $APM $BRNS $GAME $NUWE $YHC
0 · Reply
ShortSell3r
ShortSell3r Jul. 16 at 7:15 PM
$BRNS :)
0 · Reply
BigPablo2025
BigPablo2025 Jul. 16 at 7:10 PM
$BRNS I got blocked for calling this a pump and dump? and was right. I don't understand some people on here
0 · Reply